CAS NO. |
Products Name |
1628317-18-9 |
MI463 |
more... |
MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction. |
|
1857417-13-0 |
MI503 |
more... |
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction. |
|
|
1821908-48-8 |
SGC-2085 |
more... |
SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor with an IC50 of 50 nM. |
|
464930-42-5 |
SSR240612 |
more... |
SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively. |
|
1572510-80-5 |
AB-423 |
more... |
AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 μM/0.33-1.32 μM in cells. |
|
|
|
1402709-93-6 |
CCT241736 |
more... |
CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM). |
|
|
1261289-04-6 |
O-304 |
more... |
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a drug to treat type 2 diabetes (T2D) and associated cardiovascular complications |
|
1448169-71-8 |
TAS120(Futibatinib) |
more... |
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor. Futibatinib (TAS-120) covalently binds to a highly conserved P-loop cysteine residue in the ATP pocket of FGFR. Futibatinib (TAS-120) exhibits potency at low nanomolar concentrations and high specificity against wild-type FGFR1/2/3/4 as well as against some FGFR2 kinase domain mutations |
|